Name

Enable Medicine

Legal name

Enable Medicine, Inc.

Website

https://enablemedicine.com

Company type

Private

Founded year

2021

Operating status

Acquired

Headcount range

11–50 employees

Ownership category

akta.pro rank

Headquarters

HQ city

Menlo Park

HQ country

United States

HQ region

North America

Offices5 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations

Revenue model

1. Platform Subscription Services: Enable Medicine offers subscription-based access to its cloud platform for data indexing, analysis, and biological search. Based on Terms of Use language referencing service subscription fees, automatic renewal, and payment processing, the primary revenue model is recurring subscription licensing with platform access as the core offering.
2. Professional Services and Tailored Analysis: The company provides tailored analysis services where Enable scientists conduct customized research and generate insights reports for specific biological queries, supporting program goals around mechanism of action, biomarker identification, and patient stratification.

Go-to-market motion3 records

Distribution channels2 records

Marketing channels6 records

Core offering

Enable Medicine provides a cloud-based biological data platform that integrates, indexes, and analyzes multimodal biological data—including single-cell, spatial proteomics, transcriptomics, imaging, and clinical metadata—into searchable biological atlases. Its AI/ML-powered infrastructure (including the SPACE-GM geometric deep learning framework and 7-UP in silico multiplexed imaging) supports biopharma, academic, and clinical researchers in target identification, biomarker discovery, patient stratification, and mechanism-of-action studies for therapeutic development. The platform also offers tailored analysis services performed by Enable scientists.

Product overview

Enable Medicine offers a unified cloud-based platform for indexing, analyzing, and searching multimodal biological data. The core Enable Medicine Platform integrates with various spatial biology assay technologies (PhenoCycler, CODEX, Imaging Mass Cytometry, 10X Visium) and provides end-to-end capabilities: biological atlas construction, AI-powered insights generation, and dynamic discovery search. The platform is complemented by open-source tools including emObject (spatial omics data abstraction), SpatialMap (R package for spatial biology analysis), and specialized AI models like SPACE-GM (geometric deep learning for outcome prediction), 7-UP (in silico multiplexed imaging), PEPSI (polarity analysis), and SCGP (tissue structure characterization). Research services support biopharma, academic institutions, and healthcare providers with over 200 active collaborators.

Differentiator

Problem solved

Functional benefit

Products and services

• Enable Medicine Platform End-to-end cloud-based platform for generating, analyzing, and indexing high-parameter biological data. Integrates multimodal data including single-cell, spatial, transcriptomics, proteomics, and imaging into searchable biological atlases with AI-powered insights generation. Sold to biopharma and academic research organizations.
• Biological Atlas

Quantifiable outcome

• ROC-AUC above 0.85 for cancer outcome classification across hundreds of patient tissue samples
• +4 more outcomes

Named customers14 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration9 records

AI capability9 records

Feature7 records

Partnerships

Two partnerships are on record, tiered core.

• Akoya BiosciencescoreTechnology or Integration · 20 December 2023Partnership announced December 20, 2023 to introduce a cloud platform for faster analysis of PhenoCycler-Fusion data. Enables seamless integration between Akoya's multiplex immunofluorescence technology and Enable Medicine's cloud analysis platform.
• Canopy BiosciencescoreTechnology or Integration · 20 December 2023Partnership announced December 20, 2023 to bring advanced spatial analysis pipelines to the ChipCytometry Platform. Integrates Canopy's high-plex spatial biology capabilities with Enable Medicine's analysis expertise.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• 10x Genomics: Leading spatial biology and single-cell platform provider with Visium and Xenium assays. Competes with Enable in spatial transcriptomics workflows and offers its own downstream analytics that overlap with Enable's platform capabilities.
• NanoString Technologies (Bruker Spatial Biology): Acquired by Bruker; provides GeoMx digital spatial profiling and CosMx SMI spatial molecular imaging. Competes with Enable's biological atlas approach through instrument-tied data and analytics.
• Visiopharm: Digital pathology and AI tissue analysis platform serving biopharma and clinical research. Competes with Enable in image-based AI analysis of tissue samples for biomarker discovery.

Direct peers

• Akoya Biosciences: Provider of multiplex spatial biology assays (PhenoCycler-Fusion, CODEX, PhenoImager HT) and an integrated cloud analysis platform. Akoya is both a technology partner and a direct competitor in spatial analytics.
• Standard BioTools (formerly Fluidigm): Provider of Imaging Mass Cytometry (IMC) and Hyperion instruments for high-plex spatial proteomics, a core assay type that feeds into Enable's platform. Competes in spatial biology analysis workflows.
• Canopy Biosciences: Provider of the ChipCytometry spatial biology platform and high-plex tissue imaging services. Partnered with Enable but also offers competing analysis pipelines for spatial omics data.

Emerging players

• PathAI: AI-powered pathology platform that combines computer vision with biological data to support drug discovery and clinical diagnostics. Overlaps with Enable in AI-driven tissue analysis and biopharma partnership model.
• Recursion Pharmaceuticals: AI-driven drug discovery company using high-content imaging and multimodal data. Shares with Enable the AI-for-biopharma value proposition and enterprise data infrastructure thesis.
• Owkin: AI biotech building multimodal biological data models (including spatial) for drug discovery with biopharma partners. Comparable in combining AI methods with large-scale biological data assets.
• Insitro: Machine learning-driven drug discovery company combining high-dimensional biological data with predictive models. Comparable in applying AI/ML to multimodal biological data for therapeutic discovery.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/enable-medicine
• Xx.com/enablemedicine

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds2 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Enable Medicine